Intradermal injections of equine allogeneic umbilical cord-derived mesenchymal stem cells are well tolerated and do not elicit immediate or delayed hypersensitivity reactions

References

• Arnhold SJ, Goletz I, Klein H, Stumpf G, Beluche LA, Rohde C, . Isolation and characterization of bone marrow-derived equine mesenchymal stem cells. Am J Vet Res. 2007; 68:1095–105.
   Google Scholar
• Fortier LA, Nixon AJ, Williams J, Cable CS. Isolation and chondrocytic differentiation of equine bone marrow-derived mesenchymal stem cells. Am J Vet Res. 1998;59:1182–7.
   PubMed Web of Science ®Google Scholar
• Toupadakis CA, Wong A, Genetos DC, Cheung WK, Borjesson DL, Ferraro GL, . Comparison of the osteogenic potential of equine mesenchymal stem cells from bone marrow, adipose tissue, umbilical cord blood, and umbilical cord tissue. Am J Vet Res. 71:1237–45.
   Google Scholar
• Vidal MA, Kilroy GE, Johnson JR, Lopez MJ, Moore RM, Gimble JM. Cell growth characteristics and differentiation frequency of adherent equine bone marrow-derived mesenchymal stem cells: adipogenic and osteogenic capacity. Vet Surg. 2006;35:601–10.
   PubMedGoogle Scholar
• Vidal MA, Kilroy GE, Lopez MJ, Johnson JR, Moore RM, Gimble JM. Characterization of equine adipose tissue-derived stem cells: adipogenic and osteogenic capacity and comparison with bone marrow-derived mesenchymal stem cells. Vet Surg. 2007;36:613–22.
   PubMed Web of Science ®Google Scholar
• Carrade DD, Owens SD, Galuppo LD, Vidal MA, Ferraro GL, Librach F, . Clinicopathologic findings following intra-articular injection of autologous and allogeneic placentally derived equine mesenchymal stem cells in horses. Cytotherapy. 2011;13:419–30.
   PubMed Web of Science ®Google Scholar
• Passeri S, Nocchi F, Lamanna R, Lapi S, Miragliotta V, Giannessi E, . Isolation and expansion of equine umbilical cord-derived matrix cells (EUCMCs). Cell Biol Int. 2009;33:100–5.
   Google Scholar
• Koch TG, Heerkens T, Thomsen PD, Betts DH. Isolation of mesenchymal stem cells from equine umbilical cord blood. BMC Biotechnol. 2007;7:26.
   PubMed Web of Science ®Google Scholar
• Koch TG, Thomsen PD, Betts DH. Improved isolation protocol for equine cord blood-derived mesenchymal stem cells. Cytotherapy. 2009;11:443–7.
   Web of Science ®Google Scholar
• Schuh EM, Friedman MS, Carrade DD, Li J, Heeke D, Oyserman SM, . Identification of variables that optimize isolation and culture of multipotent mesenchymal stem cells from equine umbilical-cord blood. Am J Vet Res. 2009;70:1526–35.
   Google Scholar
• Conconi MT, Burra P, Di Liddo R, Calore C, Turetta M, Bellini S, . CD105(+) cells from Wharton's jelly show in vitro and in vivo myogenic differentiative potential. Int J Mol Med. 2006;18:1089–96.
   PubMed Web of Science ®Google Scholar
• Ma L, Feng XY, Cui BL, Law F, Jiang XW, Yang LY, . Human umbilical cord Wharton's jelly-derived mesenchymal stem cell differentiation into nerve-like cells. Chin Med J (Engl). 2005;118:1987–93.
   PubMed Web of Science ®Google Scholar
• Mitchell KE, Weiss ML, Mitchell BM, Martin P, Davis D, Morales L, . Matrix cells from Wharton's jelly form neurons and glia. Stem Cells. 2003;21:50–60.
   PubMed Web of Science ®Google Scholar
• Chang CJ, Yen ML, Chen YC, Chien CC, Huang HI, Bai CH, . Placenta-derived multipotent cells exhibit immunosuppressive properties that are enhanced in the presence of interferon-gamma. Stem Cells. 2006;24:2466–77.
   PubMed Web of Science ®Google Scholar
• Li C, Zhang W, Jiang X, Mao N. Human-placenta-derived mesenchymal stem cells inhibit proliferation and function of allogeneic immune cells. Cell Tissue Res. 2007;330:437–46.
   PubMed Web of Science ®Google Scholar
• Suzdaltseva YG, Burunova VV, Vakhrushev IV, Cheglakov IB, Yarygin KN. In vitro comparison of immunological properties of cultured human mesenchymal cells from various sources. Bull Exp Biol Med. 2008;145:228–31.
   Google Scholar
• Weiss ML, Anderson C, Medicetty S, Seshareddy KB, Weiss RJ, Vander Werff I, . Immune properties of human umbilical cord Wharton's jelly-derived cells. Stem Cells. 2008;26:2865–74.
   PubMed Web of Science ®Google Scholar
• Najar M, Raicevic G, Boufker HI, Fayyad Kazan H, De Bruyn C, Meuleman N, . Mesenchymal stem cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: combined comparison of adipose tissue, Wharton's jelly and bone marrow sources. Cell Immunol. 2010;264:171–9.
   PubMed Web of Science ®Google Scholar
• Kinkaid HY, Huang XP, Li RK, Weisel RD. What's new in cardiac cell therapy? Allogeneic bone marrow stem cells as ‘universal donor cells’. J Card Surg. 2010;25:359–66.
   PubMed Web of Science ®Google Scholar
• Tolar J, Le Blanc K, Keating A, Blazar BR. Concise review. Hitting the right spot with mesenchymal stem cells. Stem Cells. 2010;28:1446–55.
   PubMed Web of Science ®Google Scholar
• Prigozhina TB, Khitrin S, Elkin G, Eizik O, Morecki S, Slavin S. Mesenchymal stem cells lose their immunosuppressive potential after allotransplantation. Exp Hematol. 2008;36:1370–6.
   PubMed Web of Science ®Google Scholar
• Poncelet AJ, Vercruysse J, Saliez A, Gianello P. Although pig allogeneic mesenchymal stem cells are not immunogenic in vitro, intracardiac injection elicits an immune response in vivo. Transplantation. 2007;83:783–90.
   PubMed Web of Science ®Google Scholar
• Arinzeh TL, Peter SJ, Archambault MP, van den Bos C, Gordon S, Kraus K, . Allogeneic mesenchymal stem cells regenerate bone in a critical-sized canine segmental defect. J Bone Joint Surg Am. 2003;85A:1927–35.
   Web of Science ®Google Scholar
• Guest DJ, Smith MR, Allen WR. Monitoring the fate of autologous and allogeneic mesenchymal progenitor cells injected into the superficial digital flexor tendon of horses: preliminary study. Equine Vet J. 2008;40:178–81.
   PubMed Web of Science ®Google Scholar
• Kode JA, Mukherjee S, Joglekar MV, Hardikar AA. Mesenchymal stem cells: immunobiology and role in immunomodulation and tissue regeneration. Cytotherapy. 2009;11:377–91.
   PubMed Web of Science ®Google Scholar
• Newman RE, Yoo D, Le Roux MA, Danilkovitch-Miagkova A. Treatment of inflammatory diseases with mesenchymal stem cells. Inflamm Allergy Drug Targets. 2009;8:110–23.
   PubMedGoogle Scholar
• Sotiropoulou PA, Papamichail M. Immune properties of mesenchymal stem cells. Methods Mol Biol. 2007;407:225–43.
   Google Scholar
• Duan X, Yang L, Dong S, Xin R, Chen G, Guo L. Characterization of EGFP-labeled mesenchymal stem cells and redistribution of allogeneic cells after subcutaneous implantation. Arch Orthop Trauma Surg. 2008;128:751–9.
   Google Scholar
• Cho PS, Messina DJ, Hirsh EL, Chi N, Goldman SN, Lo DP, . Immunogenicity of umbilical cord tissue derived cells. Blood. 2008;111:430–8.
   PubMed Web of Science ®Google Scholar
• Batten P, Sarathchandra P, Antoniw JW, Tay SS, Lowdell MW, Taylor PM, . Human mesenchymal stem cells induce T cell anergy and downregulate T cell allo-responses via the TH2 pathway: relevance to tissue engineering human heart valves. Tissue Eng. 2006;12:2263–73.
   PubMedGoogle Scholar
• Keyser KA, Beagles KE, Kiem HP. Comparison of mesenchymal stem cells from different tissues to suppress T-cell activation. Cell Transplant. 2007;16:555–62.
   PubMed Web of Science ®Google Scholar
• Prevosto C, Zancolli M, Canevali P, Zocchi MR, Poggi A. Generation of CD4 + or CD8 + regulatory T cells upon mesenchymal stem cell–lymphocyte interaction. Haematologica. 2007;92:881–8.
   PubMedGoogle Scholar
• Akle CA, Adinolfi M, Welsh KI, Leibowitz S, McColl I. Immunogenicity of human amniotic epithelial cells after transplantation into volunteers. Lancet. 1981;2:1003–5.
   PubMed Web of Science ®Google Scholar
• Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, . Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol. 2002;30:42–8.
   PubMed Web of Science ®Google Scholar
• Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EG, Willemze R, Fibbe WE. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood. 2006;108:2114–20.
   PubMed Web of Science ®Google Scholar
• Duthie MS, Reece ST, Lahiri R, Goto W, Raman VS, Kaplan J, . Antigen-specific cellular and humoral responses are induced by intradermal Mycobacterium leprae infection of the mouse ear. Infect Immun. 2007;75:5290–7.
   Google Scholar
• Vukmanovic-Stejic M, Reed JR, Lacy KE, Rustin MH, Akbar AN. Mantoux test as a model for a secondary immune response in humans. Immunol Lett. 2006;107:93–101.
   PubMed Web of Science ®Google Scholar
• Wong DM, Buechner-Maxwell VA, Manning TO, Ward DL. Evaluation of the precision of intradermal injection of control substances for intradermal testing in clinically normal horses. Am J Vet Res. 2005;66:1341–7.
   Google Scholar
• Wong DM, Buechner-Maxwell VA, Manning TO, Ward DL. Comparison of results for intradermal testing between clinically normal horses and horses affected with recurrent airway obstruction. Am J Vet Res. 2005;66:1348–55.
   Google Scholar
• Bartholemew S, Owens SD, Ferraro GL, Carrade DD, Lara DJ, Librach F, . Collection of equine cord blood and placental tissues in forty thoroughbred mares. Equine Vet J. 2009;41:724–8.
   Google Scholar
• Banks KL, Greenlee A. Isolation and identification of equine lymphocytes and monocytes. Am J Vet Res. 1981;42:1651–4.
   Google Scholar
• McIntosh K, Zvonic S, Garrett S, Mitchell JB, Floyd ZE, Hammill L, . The immunogenicity of human adipose-derived cells: temporal changes in vitro. Stem Cells. 2006;24:1246–53.
   PubMed Web of Science ®Google Scholar
• Najar M, Rouas R, Raicevic G, Boufker HI, Lewalle P, Meuleman N, . Mesenchymal stem cells promote or suppress the proliferation of T lymphocytes from cord blood and peripheral blood: the importance of low cell ratio and role of interleukin-6. Cytotherapy. 2009;11:570–83.
   PubMed Web of Science ®Google Scholar
• Bradley LM. Cell proliferation. Mishell BB, Shiigi SM. San Francisco: W.H. Freeman and Company; 1980. Selected Methods in Cellular Immunology. 153–72.
   Google Scholar
• Hodgin EC, McGuire TC, Perryman LE, Grant BD. Evaluation of delayed hypersensitivity responses in normal horses and immunodeficient foals. Am J Vet Res. 1978;39:1161–7.
   Google Scholar
• Jose-Cunilleras E, Kohn CW, Hillier A, Saville WJ, Lorch G. Intradermal testing in healthy horses and horses with chronic obstructive pulmonary disease, recurrent urticaria, or allergic dermatitis. J Am Vet Med Assoc. 2001;219:1115–21.
   Google Scholar
• Yu J, Zheng C, Ren X, Li J, Liu M, Zhang L, . Intravenous administration of bone marrow mesenchymal stem cells benefits experimental autoimmune myasthenia gravis mice through an immunomodulatory action. Scand J Immunol. 2010;72:242–9.
   PubMed Web of Science ®Google Scholar
• Crop MJ, Baan CC, Korevaar SS, Ijzermans JN, Alwayn IP, Weimar W, . Donor-derived mesenchymal stem cells suppress alloreactivity of kidney transplant patients. Transplantation. 2009;87:896–906.
   PubMed Web of Science ®Google Scholar
• Vidal M, Walker NJ, Napoli E, Borjesson DL. Evaluation of senescence in mesenchymal stem cells isolated from equine bone marrow, adipose tissue and umbilical cord tissue. Stem Cells Dev. 2011 May 6 [epub ahead of print].
   Google Scholar
• Cui L, Yin S, Liu W, Li N, Zhang W, Cao Y. Expanded adipose-derived stem cells suppress mixed lymphocyte reaction by secretion of prostaglandin E2. Tissue Eng. 2007;13:1185–95.
   PubMedGoogle Scholar
• Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol. 2003;57:11–20.
   PubMed Web of Science ®Google Scholar